NeuroSense Therapeutics Ltd. (NRSN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Alon Ben-Noon
|
Co-Founder, CEO & Director | 392k | -- | 1979 |
|
Mr. Or Eisenberg
|
Chief Financial Officer | 273k | -- | 1981 |
|
Dr. Niva Russek-Blum Ph.D.
|
Chief Technology Officer | 201k | -- | 1979 |
NeuroSense Therapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 17
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
